WO2021185337A1 - 一种双特异性融合蛋白及其应用 - Google Patents
一种双特异性融合蛋白及其应用 Download PDFInfo
- Publication number
- WO2021185337A1 WO2021185337A1 PCT/CN2021/081659 CN2021081659W WO2021185337A1 WO 2021185337 A1 WO2021185337 A1 WO 2021185337A1 CN 2021081659 W CN2021081659 W CN 2021081659W WO 2021185337 A1 WO2021185337 A1 WO 2021185337A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- acid sequence
- fusion protein
- binding domain
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 142
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 142
- 230000027455 binding Effects 0.000 claims abstract description 153
- 239000012634 fragment Substances 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 238
- 238000006467 substitution reaction Methods 0.000 claims description 74
- 206010028980 Neoplasm Diseases 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 62
- 229940027941 immunoglobulin g Drugs 0.000 claims description 58
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 57
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 56
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 53
- -1 A33 Proteins 0.000 claims description 50
- 102000005962 receptors Human genes 0.000 claims description 50
- 108020003175 receptors Proteins 0.000 claims description 50
- 239000003446 ligand Substances 0.000 claims description 49
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 40
- 108091008605 VEGF receptors Proteins 0.000 claims description 36
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 102100038664 Fibrinogen-like protein 1 Human genes 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 18
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 18
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 18
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 18
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 18
- 102000054189 human CD80 Human genes 0.000 claims description 18
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 18
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 17
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 17
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 17
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 17
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 17
- 108010048507 poliovirus receptor Proteins 0.000 claims description 17
- 102000017578 LAG3 Human genes 0.000 claims description 16
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 15
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 15
- 102100027207 CD27 antigen Human genes 0.000 claims description 14
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 14
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 14
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 14
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 14
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 14
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 14
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 14
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 14
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 102100025221 CD70 antigen Human genes 0.000 claims description 13
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 12
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 12
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 11
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 11
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 11
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 11
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 11
- 108010042215 OX40 Ligand Proteins 0.000 claims description 11
- 102000004473 OX40 Ligand Human genes 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000019491 signal transduction Effects 0.000 claims description 11
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 10
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 10
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims description 10
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 10
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims description 10
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 10
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 10
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims description 10
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 10
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 claims description 10
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 10
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 10
- 102100026236 Interleukin-8 Human genes 0.000 claims description 10
- 102100036154 Platelet basic protein Human genes 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 9
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 9
- 102000002029 Claudin Human genes 0.000 claims description 9
- 108050009302 Claudin Proteins 0.000 claims description 9
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 9
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 8
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 8
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 8
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 7
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 7
- 102100031351 Galectin-9 Human genes 0.000 claims description 7
- 101710121810 Galectin-9 Proteins 0.000 claims description 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 7
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 7
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 7
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 7
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 7
- 102000003735 Mesothelin Human genes 0.000 claims description 7
- 108090000015 Mesothelin Proteins 0.000 claims description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 7
- 102100035486 Nectin-4 Human genes 0.000 claims description 7
- 101710043865 Nectin-4 Proteins 0.000 claims description 7
- 102000014128 RANK Ligand Human genes 0.000 claims description 7
- 108010025832 RANK Ligand Proteins 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 6
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 6
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 6
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 6
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 102000043321 human CTLA4 Human genes 0.000 claims description 6
- 229960005386 ipilimumab Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 6
- 229960003301 nivolumab Drugs 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 3
- 108010081667 aflibercept Proteins 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 229940121420 cemiplimab Drugs 0.000 claims description 3
- 238000006471 dimerization reaction Methods 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 230000033581 fucosylation Effects 0.000 claims description 2
- 102000058223 human VEGFA Human genes 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 15
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 15
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 15
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 11
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 11
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 claims 11
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 11
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 11
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 11
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 11
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 8
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 5
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 5
- 108091011896 CSF1 Proteins 0.000 claims 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 5
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 5
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 5
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 5
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 5
- 102100034980 ICOS ligand Human genes 0.000 claims 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 5
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 5
- 101150030213 Lag3 gene Proteins 0.000 claims 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 3
- 108091008794 FGF receptors Proteins 0.000 claims 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 3
- 101000829127 Homo sapiens Somatostatin receptor type 2 Proteins 0.000 claims 3
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 3
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 3
- 102100023802 Somatostatin receptor type 2 Human genes 0.000 claims 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 3
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 3
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 3
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 abstract description 12
- 230000001976 improved effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 22
- 238000011161 development Methods 0.000 description 21
- 230000018109 developmental process Effects 0.000 description 21
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 19
- 102000001301 EGF receptor Human genes 0.000 description 17
- 108060006698 EGF receptor Proteins 0.000 description 17
- 206010009944 Colon cancer Diseases 0.000 description 15
- 101710197507 Fibrinogen-like protein 1 Proteins 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 101800003838 Epidermal growth factor Proteins 0.000 description 12
- 102400001368 Epidermal growth factor Human genes 0.000 description 12
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 12
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 229940116977 epidermal growth factor Drugs 0.000 description 12
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 12
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 10
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 102000002627 4-1BB Ligand Human genes 0.000 description 6
- 102000010919 CXC chemokine receptor 3 Human genes 0.000 description 6
- 108010061300 CXCR3 Receptors Proteins 0.000 description 6
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 6
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108050006947 CXC Chemokine Proteins 0.000 description 5
- 102000019388 CXC chemokine Human genes 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 101710112748 Delta-like protein 3 Proteins 0.000 description 5
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 5
- 108091008606 PDGF receptors Proteins 0.000 description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 5
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 5
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004052 somatostatin receptor 2 Human genes 0.000 description 5
- 108090000586 somatostatin receptor 2 Proteins 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 229960003008 blinatumomab Drugs 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229960000419 catumaxomab Drugs 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 108700041286 delta Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000001875 tumorinhibitory effect Effects 0.000 description 3
- 102000009088 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710120217 Fc receptor-like protein 5 Proteins 0.000 description 2
- 101000797332 Homo sapiens Trem-like transcript 2 protein Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 2
- 102100032990 Trem-like transcript 2 protein Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950006925 emicizumab Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 238000012366 Fed-batch cultivation Methods 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101710180188 T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000012365 batch cultivation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000033998 protein modification process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000035802 rapid maturation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Definitions
- the present invention relates to a bispecific fusion protein with a novel structure and its application.
- the present invention also relates to polynucleotides, nucleic acid constructs and host cells for encoding or preparing the fusion protein.
- BsAbs Bispecific antibody
- dual targeting strategies have become one of the effective methods for the treatment of tumors and immune diseases (Kontermann R. Dual targeting strategies with bispecific antibodies[C]//MAbs.Taylor& Francis, 2012, 4(2):182-197.).
- Bispecific antibodies can specifically bind to two different antigens or epitopes (Carter P. Bispecific human IgG by design[J]. Journal of immunological methods, 2001,248(1-2): 7-15.). As early as the 1980s, Morrison et al. first prepared the first true anti-dextran and dansyl tetravalent double chain antibody by connecting single-chain antibodies with different specificities using flexible peptides and then fusion expression. Specific antibodies (Coloma M J, Morrison S L. Design and production of novel tetravalent bispecific antibodies [J]. Nature biotechnology, 1997, 15(2): 159.). However, due to the bottleneck of antibody preparation technology and the insufficiency of basic research on signal pathways, the development of bispecific antibodies has been hindered.
- bispecific antibodies In the development of bispecific antibodies, the choice of molecular structure is very important. Different bispecific antibody designs have their own advantages and disadvantages, but the design of bispecific antibodies for clinical treatment purposes must solve the following problems: First, ensure the correct coupling or pairing of two pairs (or more) of different light chains and heavy chains ; Second, maintain the independence of each binding domain of each monoclonal antibody, and when binding different epitopes at the same time, there will be no steric interference between each other; third, antibody molecules should be easy to express in mammalian cells. No complicated protein modification process is required; fourthly, it has good druggability, such as high thermal stability, high chemical stability, high solubility, not easy to polymerize, low viscosity, high expression level, suitable half-life, etc. (Spiess C ,Zhai Q, Carter P J. Alternative molecular formats and therapeutic applications for bispecific antibodies[J]. Molecular immunology, 2015, 67(2): 95-106.).
- bispecific antibodies can be divided into many types. For example, they can be divided into symmetrical and asymmetrical structures according to the symmetry of the structure. According to the presence or absence of the Fc region, they can be classified as containing Fc. The bispecific antibody of the region and the bispecific antibody without the Fc region, as well as the configuration according to the number of antigen binding regions, are classified into bivalent, trivalent, tetravalent or more valent configurations, etc.
- bispecific antibodies have developed dozens of structures (Spiess C, Zhai Q, Carter P J. Alternative molecular formats and therapeutic applications for bispecific antibodies[J]. Molecular immunoology, 2015, 67(2): 95-106.
- bispecific antibodies have diverse structures, roughly divided into 5 categories, including IgG-like bispecific antibodies, IgG-like bispecific antibodies with additional functional regions, and bispecific antibodies with different antigen-binding fragments in series , Fusion protein type bispecific antibody, chemically coupled bispecific antibody.
- IgG-like bispecific antibodies mainly uses recombinant DNA technology for structural modification.
- the constructed IgG-like bispecific antibodies have complete crystallizable fragments (ie Fc fragments), which can bind to different antigens while still retaining Fc fragment mediated ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-mediated cytotoxicity, complement-dependent cytotoxicity) and other functions, while this type of antibody also retains The characteristics of prolonging the half-life of antibodies in vivo by combining with neonatal Fc receptors (FcRn) (Ridgway J B, Presta L G, Carter P.' Knobs-into-holes' engineering of antibody CH3domains for heavy chain heterodimerization[ J].Protein Engineering, Design and Selection,1996,9(7):617-621.); IgG-like bispecific antibodies with additional functional regions are generally based on traditional IgG antibodies by means of fusion proteins, Add other specific antigen-binding fragments (that is, additional functional regions, such as single domain antibodies, single chain antibodies, etc.) on the heavy chain and/or light
- Monoclonal antibody therapeutics with up to five specificities functional enhancement through fusion of target-specific peptides[C]//MAbs.Taylor&Francis,2013,5(2):208-218.); bispecific antibodies with different antigen-binding fragments in series are passed
- the connecting peptide is obtained by connecting different Fabs, single-chain antibodies, single-domain antibodies, or antigen-binding fragments in a certain sequence (Stork R, Müller D, Kontermann R EA novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an album-binding domain from streptococcal protein G[J].Protein Engineering, Design &Selection,2007,20(11):569-576.); fusion protein type bispecific antibodies combine different specificities through linkers such as peptide fragments The antibody/antibody fragment (IgG, Fab, scFv, etc.) is connected to form a protein molecule that
- Tumor antigens include Claudin 18.2, HER-2, Mesothelin, BCMA, SSTR2, GPRC5D, PSMA, FCRH5, CD33, CD123, CD20, A33, CEA, CD28, DLL3, EGFR, VEGFR, VEGFR2, VEGF-A, Nectin-4, FGFR, C-met, RANKL, PDGF, PDGFR, PDGFR ⁇ , DLL4, Ang-1, Ang-2, etc.
- MEDI5752 A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells.Cancer Res.78(13),Supplement.Abstract 2776:(2018).Hedvat,M.etal.Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptortargeting with bispecific antibodies promotes enhanced human T cell activation[abstract P664].
- SITC Society for Immunotherapy of Cancer
- Aran F. Labrijn, etpipeal. Bispecific Antibodies a mechanism review of the Drug Review, NatureRecovery volume 18, pages585–608 (2019).
- bispecific antibodies are still in the clinical or preclinical research stage. Only three bispecific antibodies have been approved for the market. They are Trion Pharma’s Catumaxomab (delisted due to commercial factors in 2017) and Amgen’s Blinatumomab And Roche's Emicizumab. Catumaxomab is an IgG-like bispecific antibody in the form of Triomab.
- Blinatumomab is a bispecific antibody without Fc region and adopts the BiTE (bispecific T cell engager) structure.
- Emicizumab is a modified humanized bispecific IgG4 monoclonal antibody that can bind factor IXa and factor X.
- the antibody uses "Knobs-into-Holes (KiH)" for Fc design, “Common Light Chain-IgG (CLC-IgG)” for LC design, and "Multidimensional Optimization” for variable region optimization.
- KiH Knobs-into-Holes
- CLC-IgG Common Light Chain-IgG
- Multidimensional Optimization for variable region optimization.
- bispecific antibodies/platforms and 3 marketed drugs research and development experience due to the complex structure of bispecific antibodies and diverse functions, there are more problems and problems in their development than general antibodies. challenge.
- IgG-like bispecific antibodies face the problem of heavy chain-heavy chain or heavy chain-light chain mismatches during the preparation process.
- the most typical one is Catumaxomab.
- Catumaxomab is the first bispecific antibody approved for marketing, At the same time, it also has very obvious limitations, which are mainly reflected in the complex production process of Triomab antibody and the immunogenicity problem that heterologous antibodies are relatively easy to produce.
- bispecific antibodies have many problems, such as low expression, poor stability, complex production processes, and significantly higher research and development costs than monoclonal antibodies, all of which limit the development of bispecific antibodies. Therefore, there is an urgent need to develop bispecific antibodies with new structures to provide more clinical options.
- the present invention provides a bispecific fusion protein with a novel structure, which belongs to an IgG-like bispecific fusion protein containing additional functional regions. Specifically, the fusion protein is inserted into the second binding domain through an optional peptide linker in the hinge region of a full-length immunoglobulin G (IgG), and the Fab region of the IgG is the first of the fusion protein.
- IgG immunoglobulin G
- Binding domain the heavy chain of the IgG after the insertion of the second binding domain is the heavy chain of the fusion protein, and the light chain of the IgG is the light chain of the fusion protein; the second binding domain is selected From human receptors, ligands, fragments of the extracellular region of the receptors or ligands, binding domain fragments, or combinations of fragments; wherein the receptors or ligands are dimerized or combined in the natural signal pathway
- the multimerization structure activates or inhibits the receptor or ligand of the signaling pathway, and the second binding domain and the first binding domain target different targets.
- Hibody structural fusion protein or Hibody Hibody structural fusion protein
- the first binding domain is targeted to bind immune checkpoint molecules or tumor antigens.
- the immune checkpoint molecules include PD-1 (Programmed cell death protein 1), PD-L1 (Programmed cell death 1 ligand 1), CTLA-4 (Cytotoxic T lymphocyte-associated antigen-4), LAG-3 (Lymphocyte activation gene-3), FGL1 (Fibrinogen-like protein 1), TIM-3 (T cell immunoglobulin-3), Galectin-9, TIGIT (T-cell immunoreceptor with Ig and ITIM domains), CD155, CD47;
- the tumor antigens include Claudin 18.2, Her-2 (Human epidermal growth factor receptor-2), Mesothelin, BCMA (B Cell Maturation Antigen), SSTR2 (Somatostatin receptor 2), GPRC5D (G-protein coupled receptor family C SMA member) (Prostate specific membrane antigen), FcRH5 (Fc receptor-like protein 5), CD33, CD123, CD20, A33, CEA (Carcino-embryonic antigen), CD28, DLL3 (Delta-like protein 3
- the second binding domain targets and binds human TGF- ⁇ (Transforming growth factor- ⁇ ), CTLA-4, VEGF, LAG3, CD27, 4-1BB (CD137), OX40 (CD134), CD47, FGL1 (Fibrinogen Like Protein 1), TLT-2 (Trem-like transcript 2), CD28, HGF (Hepatocyte growth factor), CSF1 (Colony-stimulating factor 1), CXCL1 (CXC chemokine ligand 1), CXCL2 (CXC chemokine) ), CXCL3(CXCchemokine ligand 3), CXCL5(CXCchemokineligand5), CXCL6(CXCchemokineligand 6), CXCL7(CXCchemokineligand7), CXCL8(CXCchemokineCligand),XCL8(CXCchemokineCligand9, XCLchemokineCligand9, XCL (CXC chemokine ligand 10),
- the receptor or ligand is human TGF- ⁇ receptor (TGF- ⁇ R), CD80, CD86, VEGFR, VEGF-trap, FGL1, CD70, 4-1BBL, OX40L, SIRP ⁇ (Signal regulatory protein ⁇ ), B7-H3 (CD276), C-met, CSF1R (Colony-stimulating factor 1 receptor), CXCR2 (CXC chemokine receptor 2), CXCR3 (CXC chemokine receptor 3), CXCR4 (CXC chemokine receptor-induced (GlucocRL) TNF receptor ligand), EGFR, ICOS (Inducible co-stimulator).
- both CD80 and CD86 are transmembrane glycoproteins, which are members of the immunoglobulin superfamily (IgSF).
- the mature CD80 molecule consists of 254 amino acids, including 208 amino acids in the extracellular domain (ECD), 25 amino acids in the transmembrane domain, and 21 amino acids in the intracellular domain.
- the mature CD86 molecule is composed of 303 amino acids, of which the extracellular domain is 222 amino acids, the transmembrane domain is 20 amino acids, and the intracellular domain is 61 amino acids.
- the extracellular domains of CD80 and CD86 include immunoglobulin V (IgV) and immunoglobulin C (IgC) regions.
- CD80 and CD86 bind to their ligands CD28 and CTLA-4 through the immunoglobulin V (IgV) region.
- IgV immunoglobulin V
- CD80 and CD86 play an important regulatory role in antigen-induced T cell activation, proliferation and effector function production, and are positive regulators; while in the case of CD80 and CD86 binding to CTLA-4, CD80 And CD86 down-regulates the immune response and is a negative regulator. Therefore, CD80 and CD86 are co-stimulatory factors when T lymphocytes are activated, and they play an important role in autoimmune monitoring, humoral immune response and transplantation response.
- CD28 ligand CD80 as an activating factor to activate T cells is different from using agonistic anti-CD28 antibodies to activate T cells. It does not trigger a severe cytokine storm, thereby greatly reducing the possibility of endangering the life of the patient.
- the CD80 ECD is selected from human CD80 (such as human CD80 of SEQ ID NO: 134) or human CD80 ECD from CD80 isotype 2 or isotype 3 (SEQ ID NO: 135 and 136).
- the CD80ECD includes a CD80 immunoglobulin V (IgV) region (CD80-IgV, SEQ ID NO: 133).
- the CD80 ECD comprises human CD80 immunoglobulin V region and C region (CD80-IgVIgC, SEQ ID NO: 32).
- the CD80 ECD is human CD80 ECD, and in one embodiment, the CD80 ECD comprises human CD80 IgV.
- CD80-IgV (SEQ ID NO: 133):
- CD80-IgVIgC (SEQ ID NO: 32):
- CD80 isotype 1 (SEQ ID NO: 134):
- CD80 isotype 2 (SEQ ID NO: 135):
- CD80 isotype 3 (SEQ ID NO: 136):
- first binding domain and the second binding domain are selected from the following combinations:
- the first binding domain targets PD-L1
- the second binding domain targets human TGF- ⁇ , VEGF, FGL1, CD47, CD155, HGF, CSF1, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL12, EGF or ICOSL; or
- the first binding domain targets PD-1
- the second binding domain targets human CTLA-4, VEGF, HGF, EGF, CD28, LAG3, CD27, 4-1BB or OX40; or
- the first binding domain targets CTLA-4, and the second binding domain targets human CD28, VEGF, HGF, EGF, LAG3, CD27, 4-1BB or OX40; or
- the first binding domain targets LAG-3
- the second binding domain targets human CD28, VEGF, HGF, EGF, CTLA-4, CD27, 4-1BB or OX40; or
- the first binding domain targets FGL1, and the second binding domain targets human TGF- ⁇ , VEGF, CD47, CD155, HGF, CSF1, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL12, EGF or ICOSL; or
- the first binding domain targets TIM-3, and the second binding domain targets human VEGF, HGF, EGF, LAG3, CD27, 4-1BB or OX40; or
- the first binding domain targets Galectin-9
- the second binding domain targets human TGF- ⁇ , VEGF, CD47, CD155, HGF, CSF1, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL12, EGF or ICOSL; or
- the first binding domain targets TIGIT
- the second binding domain targets human TGF- ⁇ , HGF, EGF or VEGF; or
- the first binding domain targets CD155
- the second binding domain targets human TGF- ⁇ , VEGF, HGF, EGF, CD47 or CD155; or
- the first binding domain targets Claudin 18.2, HER-2, mesothelin, BCMA, SSTR2, GPRC5D, PSMA, FCRH5, CD33, CD123, CD20, A33, CEA, CD28, DLL3, EGFR, VEGFR, VEGFR2, VEGF-A, Nectin-4, FGFR, C-met, RANKL, PDGF, PDGFR, PDGFR ⁇ , DLL-4, Ang-1, Ang-2, the second binding domain targets human CTLA-4 , TGF- ⁇ , VEGF, FGL1, LAG3, 4-1BB, OX40, CD27, CD28, CD47, CD155, HGF, CSF1, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL12, EGF Or ICOSL.
- first binding domain, the receptor, and the ligand are selected from the following combinations:
- the first binding domain targets PD-L1, and the receptor and ligand are selected from the group consisting of TGF- ⁇ RII, VEGFR, LAG-3, SIRP ⁇ , TIGIT, C-MET, CSF1R, CXCR2, CXCR3, CXCR4, EGFR or ICOS; or
- the first binding domain targets PD-1, and the receptor and ligand are selected from human CD80, CD86, VEGFR, c-MET, EGFR, FGL1, CD70, 4-1BBL or OX40L; or
- the first binding domain targets CTLA-4, and the receptor and ligand are selected from human CD80, CD86, VEGFR, c-MET, EGFR, FGL1, CD70, 4-1BBL or OX40L; or
- the first binding domain targets LAG-3 are selected from human VEGFR, c-MET, EGFR, CD80, CD86, CD70, 4-1BBL or OX40L; or
- the first binding domain targets FGL1, and the receptor and ligand are selected from human TGF- ⁇ RII, VEGFR, SIRP ⁇ , TIGIT, c-MET, CSF1R, CXCR2, CXCR3, CXCR4, EGFR or ICOS ;or
- the first binding domain targets TIM-3, and the receptor and ligand are selected from human VEGFR, c-MET, EGFR, FGL1, CD70, 4-1BBL or OX40L; or
- the first binding domain targets Galectin-9 are selected from the group consisting of human TGF- ⁇ RII, VEGFR, SIRP ⁇ , TIGIT, c-MET, CSF1R, CXCR2, CXCR3, CXCR4, EGFR Or ICOS; or
- the first binding domain targets TIGIT and the receptor and ligand are selected from human TGF- ⁇ RII, c-MET, EGFR or VEGFR; or
- the first binding domain targets CD155 are selected from human TGF- ⁇ RII, VEGFR, c-MET, EGFR, SIRP ⁇ or TIGIT; or
- the first binding domain targets Claudin 18.2, HER-2, mesothelin, BCMA, SSTR2, GPRC5D, PSMA, FCRH5, CD33, CD123, CD20, A33, CEA, CD28, DLL3, EGFR, VEGFR, VEGFR2, Nectin-4, FGFR, c-MET, RANKL, PDGF, PDGFR, PDGFR ⁇ , DLL4, Ang-1 or Ang-2, the receptor and ligand are selected from human CTLA-4, CD80, CD86, TGF- ⁇ RII, VEGFR, FGL1, LAG3, 4-1BB, OX40, CD27, CD28, CD70, c-MET, SIRP ⁇ , TIGIT, CSF1R, CXCR2, CXCR3, CXCR4, EGFR or ICOS.
- fragments of the receptors and ligands include fragments of the extracellular region of the receptors or ligands, and fragments of the binding domains.
- the first binding domain is targeted to bind PD-L1; the second binding domain is a human TGF- ⁇ RII fragment; or the first binding domain is targeted to bind PD-1, and the second binding
- the domain includes human CD80 ECD, CD80 IgV region, human CD80 IgVIgC, VEGFR1 ECD, VEGFR2 ECD, or the combination of the second extracellular region of VEGFR1 and the third extracellular region of VEGFR2; or the first binding domain targets binding Claudin 18.2 or HER-2, EGFR
- the second binding domain is selected from the group consisting of human CD80 ECD, CD80 IgV region, human CD80 IgVIgC, VEGFR1 ECD, VEGFR2 ECD or the second extracellular region of VEGFR1 and the third extracellular region of VEGFR2 Regional combination.
- the second binding domain is selected from:
- Human TGF- ⁇ RII comprising the sequence shown in SEQ ID NO: 31, 131, or 132 or containing more than 80%, 85%, 90%, or more than the sequence shown in SEQ ID NO: 31, 131 or 132. 95%, 96%, 97%, 98%, 99% sequence or 1, 2, 3, 4, 5, 6 compared with the sequence shown in SEQ ID NO: 31, 131 or 132 , 7, 8, 9, or 10 amino acid substitutions or deletions of the amino acid sequence; or
- the C-terminus or/and the N-terminus of the second binding domain has a peptide linker, and the peptide linker consists of 2-30 amino acids.
- peptide linker may be:
- TVAAPSVFIFPP SEQ ID NO: 93
- AKTTPPSVTPLAP SEQ ID NO: 97
- AKTTAP SEQ ID NO: 98
- n is equal to 1, 2, 3 or 4;
- the (GGGGS)n is GGGGS (SEQ ID NO: 120);
- the (GGGGS)n is GGGGSGGGGS (SEQ ID NO: 121) or (GGGGS) 2 ;
- the (GGGGS)n is GGGGSGGGGSGGGGS (SEQ ID NO: 122) or (GGGGS) 3 ;
- the (GGGGS)n is GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 123) or (GGGGS) 4 .
- the size of the inserted second binding domain does not exceed 235, 240, 250, 260, 270, 280, 290 or 300 amino acids.
- the insertion site of the second binding domain is located in the front part of the hinge region, and the insertion site does not affect the formation of the disulfide bond of the immunoglobulin.
- the middle front part of the hinge area usually refers to the part before 231A.
- part of the amino acids in the hinge region before and after the insertion site are replaced or deleted, for example, the hinge region contains D221G and/or C220V mutations.
- the IgG is selected from mammalian IgG, humanized IgG and human IgG.
- the mammal includes mouse and rat; preferably, the IgG is IgG1, IgG2, IgG3, and IgG4.
- the Fc region of the fusion protein is aglycosylated or deglycosylated or has reduced fucosylation or afucosylation.
- the IgG is Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, Cemiplimab, Ipilimumab.
- the IgG is Atezolizumab, the heavy chain amino acid sequence of the IgG is shown in SEQ ID NO: 106, and the light chain amino acid sequence of the IgG is shown in SEQ ID NO: 107; or the IgG is Avelumab, The heavy chain amino acid sequence of the IgG is shown in SEQ ID NO: 108, and the light chain amino acid sequence of the IgG is shown in SEQ ID NO: 109; or the IgG is Durvalumab, and the heavy chain amino acid sequence of the IgG is shown in SEQ ID NO: 110, the light chain amino acid sequence of the IgG is shown in SEQ ID NO: 111; or the IgG is Nivolumab, and the heavy chain amino acid sequence of the IgG is shown in SEQ ID NO
- the present invention provides a Hibody structural fusion protein with a first binding domain targeting human PD-L1, the CDR of the heavy chain variable region in the Fab of the IgG and/or the light chain variable region
- the CDR of the antibody has the same CDR sequence as the antibody defined by the following sequence, or 1-2 amino acid substitutions are made on the CDR of the antibody defined by the following sequence, and the antibody defined by the sequence is:
- variable region of the heavy chain is shown in SEQ ID NO: 66; and/or
- the CDRs of the heavy chain variable region and/or the CDRs of the light chain variable region in the Fab of the IgG are as follows:
- the CDR1 amino acid sequence of the heavy chain variable region is selected from SEQ ID NO: 1-5 and the amino acid sequence of SEQ ID NO: 1-5 with 1 or 2 amino acid substitutions;
- the CDR2 amino acid sequence is selected from SEQ ID NO: 6-10 and the amino acid sequence of SEQ ID NO: 6-10 after 1 or 2 amino acid substitutions;
- the CDR3 amino acid sequence is selected from SEQ ID NO: 11-15 and SEQ ID NO: 11-15 is 1 or 2 The amino acid sequence after the amino acid substitution; and/or
- the CDR1 amino acid sequence of the light chain variable region is selected from SEQ ID NO: 16-20 and the amino acid sequence of SEQ ID NO: 16-20 with 1 or 2 amino acid substitutions; the CDR2 amino acid sequence is selected from SEQ ID NO: 21-25 and the amino acid sequence of SEQ ID NO: 21-25 after 1 or 2 amino acid substitutions; the CDR3 amino acid sequence is selected from SEQ ID NO: 26-30 and SEQ ID NO: 26-30 is 1 or 2 The amino acid sequence after the amino acid substitution.
- the complementarity determining regions CDR 1-3 of the corresponding heavy chain and light chain variable regions are shown in Table 2.
- the fusion protein contains the following CDR sequences,
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 1, 6, 11 or the amino acid sequence of SEQ ID NO: 1, 6, 11 with 1 or 2 amino acid substitutions; and/or
- the CDR 1-3 amino acid sequence of the light chain variable region is SEQ ID NO: 16, 21, 26 or the amino acid sequence of SEQ ID NO: 16, 21, 26 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 2, 7, 12 or the amino acid sequence of SEQ ID NO: 2, 7, 12 with 1 or 2 amino acid substitutions; and/or
- the CDR 1-3 amino acid sequence of the light chain variable region is SEQ ID NO: 17, 22, 27 or the amino acid sequence of SEQ ID NO: 17, 22, 27 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 3, 8, 13 or the amino acid sequence of SEQ ID NO: 3, 8, 13 after 1 or 2 amino acid substitutions; and/or
- the amino acid sequence of the CDR 1-3 of the light chain variable region is SEQ ID NO: 18, 23, 28 or the amino acid sequence of SEQ ID NO: 18, 23, 28 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 4, 9, 14 or the amino acid sequence of SEQ ID NO: 4, 9, 14 after 1 or 2 amino acid substitutions; and/or
- the CDR 1-3 amino acid sequence of the light chain variable region is SEQ ID NO: 19, 24, 29 or the amino acid sequence of SEQ ID NO: 19, 24, 29 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 5, 10, 15 or the amino acid sequence of SEQ ID NO: 5, 10, 15 after 1 or 2 amino acid substitutions; and/or
- the CDR 1-3 amino acid sequence of the light chain variable region is SEQ ID NO: 20, 25, 30 or the amino acid sequence of SEQ ID NO: 20, 25, 30 with 1 or 2 amino acid substitutions.
- amino acid sequence of the CDR 1-3 of the heavy chain variable region in the heavy chain of the fusion protein is SEQ ID NO: 3, 8, 13; and/or the amino acid sequence of the CDR 1-3 of the light chain variable region is SEQ ID NO: 18, 23, 28.
- sequences of the heavy chain variable region and the light chain variable region of the fusion protein are as follows,
- variable region of the heavy chain is shown in SEQ ID NO: 66, or has the same CDR 1-3 as SEQ ID NO: 66 and is more than 80% or 85% identical to SEQ ID NO: 66 , 90%, 95%, 96%, 97%, 98%, 99% sequence; and/or
- variable region of the light chain is shown in SEQ ID NO: 67, or has the same CDR 1-3 as SEQ ID NO: 67 and the identity is greater than 80%, 85% compared with SEQ ID NO: 67 , 90%, 95%, 96%, 97%, 98%, 99% sequence.
- amino acid sequences of the heavy chain and light chain of the fusion protein are shown below,
- the heavy chain amino acid sequence of the fusion protein is shown in SEQ ID NO: 72 or is more than 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 72 sequence;
- the light chain amino acid sequence of the fusion protein is as shown in SEQ ID NO: 73 or is more than 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 73. the sequence of.
- amino acid sequences of the heavy chain and light chain of the fusion protein are as follows:
- the heavy chain amino acid sequence of the fusion protein has 1-15 amino acid site mutations or a substituted peptide linker
- the light chain amino acid sequence of the fusion protein has 1-10 amino acid site mutations.
- the present invention provides a Hibody structural fusion protein with a first binding domain targeting human PD-1, wherein the CDR of the heavy chain variable region in the Fab and/or the light chain variable region
- the CDR has the same CDR sequence as the antibody defined by the following sequence or 1-2 amino acid substitutions are made on the CDR of the antibody defined by the following sequence.
- the antibody defined by the sequence is:
- variable region of the heavy chain is shown in SEQ ID NO: 64; and/or
- the CDRs of the heavy chain variable region of the Fab in the fusion protein and/or the CDRs of the light chain variable region of the fusion protein are as follows:
- the CDR1 amino acid sequence of the heavy chain variable region is selected from SEQ ID NO: 34-38 and the amino acid sequence of SEQ ID NO: 34-38 after 1 or 2 amino acid substitutions;
- the CDR2 amino acid sequence is selected from SEQ ID NO: 39-43 and the amino acid sequence of SEQ ID NO: 39-43 after 1 or 2 amino acid substitutions;
- the CDR3 amino acid sequence is selected from SEQ ID NO: 44-48 and SEQ ID NO: 44-48 is 1 or 2 The amino acid sequence after the amino acid substitution; and/or
- the CDR1 amino acid sequence of the light chain variable region is selected from SEQ ID NO: 49-53 and SEQ ID NO: 49-53 with 1 or 2 amino acid substitutions;
- the CDR2 amino acid sequence is selected from SEQ ID NO: 54-58 and the amino acid sequence of SEQ ID NO: 54-58 with 1 or 2 amino acid substitutions;
- the CDR3 amino acid sequence is selected from SEQ ID NO: 59-63 and SEQ ID NO: 59-63 with 1 or 2 The amino acid sequence after the amino acid substitution.
- the complementarity determining regions CDR 1-3 of the corresponding heavy chain and light chain variable regions are shown in Table 3.
- CDR1-3 of the variable region of the fusion protein are defined as follows,
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 34, 39, 44 or the amino acid sequence of SEQ ID NO: 34, 39, 44 after 1 or 2 amino acid substitutions; and/or
- the amino acid sequence of the CDR 1-3 of the light chain variable region is SEQ ID NO: 49, 54, 59 or the amino acid sequence of SEQ ID NO: 49, 54, 59 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 35, 40, 45 or the amino acid sequence of SEQ ID NO: 35, 40, 45 after 1 or 2 amino acid substitutions; and/or
- the amino acid sequence of the CDR 1-3 of the light chain variable region is SEQ ID NO: 50, 55, 60 or the amino acid sequence of SEQ ID NO: 50, 55, 60 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 36, 41, 46 or the amino acid sequence of SEQ ID NO: 36, 41, 46 after 1 or 2 amino acid substitutions; and/or
- the CDR 1-3 amino acid sequence of the light chain variable region is SEQ ID NO: 51, 56, 61 or the amino acid sequence of SEQ ID NO: 51, 56, 61 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 37, 42, 47 or the amino acid sequence of SEQ ID NO: 37, 42, 47 after 1 or 2 amino acid substitutions; and/or
- the amino acid sequence of the CDR 1-3 of the light chain variable region is SEQ ID NO: 52, 57, 62 or the amino acid sequence of SEQ ID NO: 52, 57, 62 after 1 or 2 amino acid substitutions; or
- the CDR 1-3 amino acid sequence of the heavy chain variable region is SEQ ID NO: 38, 43, 48 or the amino acid sequence of SEQ ID NO: 38, 43, 48 after 1 or 2 amino acid substitutions; and/or
- the CDR 1-3 amino acid sequence of the light chain variable region is SEQ ID NO: 53, 58, 63 or the amino acid sequence of SEQ ID NO: 53, 58, 63 with 1 or 2 amino acid substitutions.
- variable region CDR1-3 of the fusion protein is defined as follows: the amino acid sequence of the heavy chain variable region CDR1-3 is SEQ ID NO: 36, 41, 46; and/or the light chain variable region CDR1
- the amino acid sequence of -3 is SEQ ID NO: 51, 56, 61.
- amino acid sequences of the heavy chain variable region and the light chain variable region of the fusion protein are as follows:
- the sequence of the heavy chain variable region is shown in SEQ ID NO: 64, or it has the same CDR 1-3 as SEQ ID NO: 64 and the identity is greater than 80%, 85% compared with SEQ ID NO: 64 , 90%, 95%, 96%, 97%, 98%, 99% sequence; and/or
- variable region of the light chain is shown in SEQ ID NO: 65, or has the same CDR 1-3 as SEQ ID NO: 65 and the identity is greater than 80%, 85% compared with SEQ ID NO: 65 , 90%, 95%, 96%, 97%, 98%, 99% sequence.
- heavy chain and light chain amino acid sequences of the fusion protein are defined as follows:
- the heavy chain amino acid sequence of the fusion protein is shown in SEQ ID NO: 68 or is more than 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 68 sequence;
- amino acid sequence of the light chain of the fusion protein is shown in SEQ ID NO: 69 or the identity is greater than 90%, 95%, 96%, 97%, 98%, 99% compared with SEQ ID NO: 69. the sequence of.
- amino acid sequences of the heavy chain and light chain of the fusion protein are as follows:
- the heavy chain amino acid sequence of the fusion protein has 1-15 amino acid site mutations or a substituted peptide linker
- the light chain amino acid sequence of the fusion protein has 1-10 amino acid site mutations.
- heavy chain and light chain amino acid sequences of the fusion protein are defined as follows:
- the heavy chain amino acid sequence of the fusion protein is shown in SEQ ID NO: 70 or is more than 90%, 95%, 96%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 70 sequence;
- the light chain amino acid sequence of the fusion protein is as shown in SEQ ID NO: 71 or is more than 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 71. the sequence of.
- amino acid sequences of the heavy chain and light chain of the fusion protein are as follows:
- the heavy chain amino acid sequence of the fusion protein has 1-15 amino acid site mutations or a substituted peptide linker
- the light chain amino acid sequence of the fusion protein has 1-10 amino acid site mutations.
- the present invention also provides an isolated polynucleotide, which encodes the fusion protein as described above.
- the present invention also provides a nucleic acid construct comprising the polynucleotide as described above, and preferably the nucleic acid construct is a vector.
- the present invention also provides a host cell comprising the polynucleotide or nucleic acid construct or vector as described above.
- the cell is a prokaryotic cell, a eukaryotic cell, a yeast cell, a mammalian cell, an E. coli cell or CHO cells, NS0 cells, Sp2/0 cells, BHK cells.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the fusion protein as described above and a pharmaceutically acceptable carrier.
- the present invention also provides a method for treating tumors or cancers, which includes the step of administering the above-mentioned fusion protein or the pharmaceutical composition to a subject in need of treatment or relief.
- the present invention also provides the use of the above-mentioned fusion protein, polynucleotide, nucleic acid construct or carrier and pharmaceutical composition in the preparation of a medicine for treating or preventing tumor or cancer.
- the tumor or cancer includes solid tumors or non-solid tumors.
- the present invention also provides a diagnostic kit, which comprises the fusion protein as described above.
- the present invention also provides a method for producing a fusion protein, the method comprising: culturing the host cell under conditions that allow the expression of the nucleic acid construct as described above, and recovering the produced fusion protein from the culture.
- the Hibody structural fusion protein provided by the present invention because the second binding domain is inserted in the hinge region, has the same expression and production advantages as IgG, and can be seamlessly connected to the existing IgG expression platform and purification platform, greatly improving The subsequent development cost is reduced.
- the bispecific antibody constructed by the Hibody platform has a higher expression level without the problem of light and heavy chain mismatches, which also greatly reduces the antibody Cost of production.
- the receptor or ligand selected as the second binding domain will form a dimerization or multimerization structure in the natural signaling pathway to activate or inhibit the signaling pathway, and when it is inserted into the hinge region, its The spatial positional relationship in the hinge region promotes the formation of the dimerization of the corresponding receptor or ligand or its fragments, thereby imitating the natural signal pathway to obtain a more significantly improved binding activity, thereby making the fusion protein relative to the use of soluble
- the activation or inhibition ability of receptors or ligands or binding fragments has been greatly improved.
- the target of receptor inhibition or receptor activation can be flexibly selected, which has an effective synergistic effect. Compared with the two target drugs being administered alone or the double-dose of the prior art Specific antibodies have a more significant disease treatment effect and can effectively treat or control the disease process, especially in various tumors and cancers.
- Figure 1 Schematic diagram of Hibody structure fusion protein.
- Figure 2 shows the tumor inhibition curve of Hib-PDV and its control group on mouse colon cancer model.
- Figure 3 shows the inhibition curve of Hib-PDC and its control group on mouse colon cancer.
- Fig. 4 is a comparison chart of Hib-PLT and its control group at a concentration of 10-100 nM to promote cell secretion of IFN- ⁇ factor.
- amino acids involved in the present invention can be represented by their commonly known three-letter symbols or by the single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission (IUPAC-IUB Biochemical Nomenclature Commission). Likewise, nucleotides can be represented by their generally accepted one-letter codes.
- the complementarity determining region (CDR) determination or numbering method of the antibody variable domain includes IMGT, Kabat (such as the sequence of proteins of interest in immunology by Kabat et al.), which are well-known in the art. Immunological Interest), 5th edition, Public Health Service, National Institutes of Health, Bethesda MD (1991), Chothia, AbM and Contact method.
- the "identity”, “identity” or “similarity” between two nucleic acid or amino acid sequences refers to the two to be compared obtained after the best alignment (optimal alignment).
- the percentage of identical nucleotides or identical amino acid residues between sequences is purely statistical and the differences between the two sequences are randomly distributed and cover their entire length.
- Sequence comparisons between two nucleic acid or amino acid sequences are usually performed by comparing these sequences after they are matched in an optimal manner, and the comparison can be performed through segments or through a "comparison window".
- the optimal alignment used to compare sequences can also be passed through the local homology algorithm of Smith and Waterman (1981) [Ad.App.Math.
- the immunoglobulin referred to in the present invention refers to an animal protein with antibody activity. It is composed of two identical light chains and two identical heavy chains. It is an important class of immune effector molecules.
- the protein produced by the lymphocytes of the immune system of higher animals can be transformed into antibodies by the induction of antigens. Due to different structures, it can be divided into 5 types: IgG, IgA, IgM, IgD and IgE.
- the immunoglobulin involved in the present invention is IgG.
- the receptor involved in the present invention is a type of receptor that exists in the cell membrane or in the cell, and can bind to a specific signal molecule outside the cell to activate a series of biochemical reactions in the cell, so that the cell responds to external stimuli.
- the biologically active substances that bind to the receptor are collectively referred to as ligands.
- the binding of receptors and ligands will cause molecular conformational changes, which will cause cellular responses, such as mediating intercellular signal transduction, intercellular adhesion, endocytosis and other processes.
- the bispecific fusion protein of the present invention is based on the immunoglobulin structure with a second binding domain inserted in its hinge region. Therefore, the bispecific fusion protein of the present invention has two binding domains.
- Hibody bispecific fusion proteins Hib-PLT, Hib-PDC, Hib-PDV;
- Control protein 1-3 constructed according to the bifunctional molecular structure in WO2015/118175;
- 3Other control proteins TGF- ⁇ -R-His, VEGF-R-His, CD80-His, PD-L1 control antibodies.
- nucleic acid sequence and amino acid sequence of the fusion protein Hib-PLT heavy chain and light chain are as follows:
- Nucleic acid sequence of fusion protein Hib-PLT heavy chain (SEQ ID NO: 78):
- Fusion protein Hib-PLT heavy chain amino acid sequence (SEQ ID NO: 72):
- the bolded framed fragment is the hinge region sequence, italicized is the peptide linker, and the underlined bolded sequence is the TGF- ⁇ RII amino acid sequence.
- Nucleic acid sequence of fusion protein Hib-PLT light chain (SEQ ID NO: 79):
- Amino acid sequence of fusion protein Hib-PLT light chain (SEQ ID NO: 73):
- nucleic acid sequence and amino acid sequence of the heavy chain and light chain of the fusion protein Hib-PDC are as follows:
- Nucleic acid sequence of fusion protein Hib-PDC heavy chain (SEQ ID NO: 74):
- the heavy chain amino acid sequence of the fusion protein Hib-PDC (SEQ ID NO: 68):
- the peptide linker is in italics, and the underlined and bold sequence is the CD80 amino acid sequence.
- Nucleic acid sequence of fusion protein Hib-PDC light chain (SEQ ID NO: 75):
- Amino acid sequence of fusion protein Hib-PDC light chain (SEQ ID NO: 69):
- nucleic acid sequence and amino acid sequence of the fusion protein Hib-PDV heavy chain and light chain are as follows:
- Nucleic acid sequence of fusion protein Hib-PDV heavy chain (SEQ ID NO: 76):
- Fusion protein Hib-PDV heavy chain amino acid sequence (SEQ ID NO: 70):
- the peptide linker is in italics, and the underlined and bold sequence is the VEGF amino acid sequence.
- Fusion protein Hib-PDV light chain nucleic acid sequence (SEQ ID NO: 77):
- Amino acid sequence of fusion protein Hib-PDV light chain (SEQ ID NO: 71):
- control protein 1 The heavy chain amino acid sequence of control protein 1 (SEQ ID NO: 124):
- the peptide linker is in italics, and the underlined and bold sequence is the amino acid sequence of TGF- ⁇ RII.
- the heavy chain amino acid sequence of the control protein 2 (SEQ ID NO: 126):
- the peptide linker is in italics, and the underlined and bold sequence is the CD80 amino acid sequence.
- control protein 3 The heavy chain amino acid sequence of control protein 3 (SEQ ID NO: 128):
- the peptide linker is in italics, and the underlined and bold sequence is the VEGFR amino acid sequence.
- TGF- ⁇ -R-His is a fragment of the TGF- ⁇ RII extracellular region of His tag, wherein the TGF-
- VEGF-R-His is a combination fragment of the second extracellular region of VEGFR1 and the third extracellular region of VEGFR2, wherein the second extracellular region of VEGFR1 and the third extracellular region of VEGFR2 Amino acid sequence of the combined fragment (SEQ ID NO: 130):
- CD80-His is the CD80 fragment of His tag, wherein the amino acid sequence of the CD80 fragment (SEQ ID NO: 32):
- the CHO host cells were resuscitated, the resuscitation culture volume was 10 mL, and the culture conditions were 37.0°C, 200 rpm, 8% CO 2 , and 80% humidity. After resuscitation, the cell density was 2.82 ⁇ 10 5 cells/mL, and the viability was 95.41%.
- the density of viable cells was 2.22 ⁇ 10 6 cells/mL, and the viability rate was 98.32%.
- the cells were rejoined at 5 ⁇ 10 5 cells/mL for cell rejoining operation. After 48 hours of continuous culture, the viable cell density was 2 ⁇ 10 6 cells/mL, and the viability was 98.68%.
- the cells were spread into a 6-well plate at 5 ⁇ 10 5 cells/well with a culture volume of 2 mL/well, and placed in a carbon dioxide incubator (cultivation conditions 37° C., 8% CO 2 ) for overnight culture for adherent transfection the next day.
- the transfection reagent is LTX Reagent (Invitrogen, catalog number 15338-100), contains LTX and Plus reagents.
- Transfection operation change the medium in the six-well plate to prepare the transfection complex: LTX: 9 ⁇ l/well + plasmid: 2.5 ⁇ g/well + plus: 2.5 ⁇ l/well, according to each well 250 ⁇ l was added to the six-well plate.
- the cells in each well of the 6-well plate were exchanged 5 hours after cell transfection. After 48 hours of transfection, the supernatant was taken, and the antibody content of the supernatant was detected by the double antigen ELISA method.
- the cells in the six-well plate were digested and collected into a cell culture tube.
- the cell density was 3 ⁇ 10 5 cells/mL for suspension adaptation and growth.
- the Hib-PLT-expressing cells pool Perform batch culture with the control protein 1 expressing cell pool, and feed Hib-PDC, control protein 2, Hib-PDV, and control protein 3 into fed-batch culture.
- Batch culture culture in a TPP cell culture tube at a cell density of 3 ⁇ 10 5 cells/mL, with a volume of 30 mL, culture conditions 37.0°C, 200 rpm, 8% CO 2 , and 80% humidity. The cell viability and metabolism are monitored every day, and the culture is terminated until the viability is less than 60%, and the cell supernatant after the culture is taken for concentration detection.
- Fed-feed culture culture in a TPP cell culture tube at a cell density of 3 ⁇ 10 5 cells/mL, with a volume of 30 mL, and culture conditions at 37.0°C, 200 rpm, 8% CO 2 , and 80% humidity.
- the cells were given concentrated medium, during which the Glc was controlled at 2-6g/L. End the culture until the viability is less than 60%, and take the cell supernatant after the end of the culture for concentration detection.
- Table 6 shows the expression results of Hibody bispecific fusion proteins Hib-PLT, Hib-PDC, Hib-PDV and the corresponding control proteins.
- the results show that the expression of Hib-PLT increases relative to the corresponding control protein.
- the relative value of the increase in expression of Hib-PDC increased by 33.43%; compared with the corresponding control protein, the relative value of the increase in expression of Hib-PDV increased by 25.6%
- the expression level of the Hibody bispecific fusion protein provided by the present invention is significantly better than the expression level of the corresponding control protein, and the bispecific antibody provided by the present invention has unexpected technical effects.
- the relative value of increase (the expression of the bispecific fusion protein provided by the present invention-the expression of the corresponding control protein)/the expression of the corresponding control protein.
- Coating antigen Dilute TGF- ⁇ 1 to 2 ⁇ g/ml with coating buffer, add 100 ⁇ l per well to a 96-well plate, and let stand overnight at 2-8°C;
- each concentration point of the sample is as follows, 100 ⁇ l of each concentration point sample is added to a 96-well plate in turn, each concentration point is paralleled with 2 replicate wells, and incubated at 37°C for 2 hours;
- ⁇ Hib-PLT sample well After Goat-anti-Human-Fc-HRP is diluted 1:5000, 100 ⁇ l per well, incubate at 37°C for 2 hours;
- ⁇ TGF- ⁇ -R-His well After Anti-His-HRP is diluted 1:5000, 100 ⁇ l per well, incubate at 37°C for 2 hours;
- TMB color development solution, 100 ⁇ l each well develops color for 2 minutes;
- Stop color development 2M H 2 SO 4 is the stop solution, 50 ⁇ l per well to stop color development;
- Reading MD microplate reader reads the absorbance value at 450/655nm respectively, taking the concentration of the sample to be tested as the abscissa and the absorbance value as the ordinate to make a 4-PL curve, and the software automatically gives the EC50 value.
- Coating antigen Dilute VEGF to 1 ⁇ g/ml with coating buffer, add 100 ⁇ l per well to a 96-well plate, and let stand overnight at 2 ⁇ 8°C;
- each concentration point of the sample is as follows, 100 ⁇ l of each concentration point sample is added to a 96-well plate in turn, each concentration point is paralleled with 2 replicate wells, and incubated at 37°C for 2 hours;
- ⁇ Hib-PDV sample well Goat-anti-Human-Fc-HRP diluted 1:5000, 100 ⁇ l per well, incubate at 37°C for 2 hours;
- ⁇ VEGFR-His well Anti-His-HRP diluted 1:5000, 100 ⁇ l per well, incubate at 37°C for 2 hours
- TMB color development solution, 100 ⁇ l each well develops color for 2 minutes;
- Stop color development 2M H2SO4 is the stop solution, 50 ⁇ l per well to stop color development;
- Reading MD microplate reader reads the absorbance value at 450/655nm respectively, taking the concentration of the sample to be tested as the abscissa and the absorbance value as the ordinate to make a 4-PL curve, and the software automatically gives the EC50 value.
- Coating antigen Reconstitute CTLA-4Protein with 1 mL of sterilized water at a concentration of 200ug/mL. Dilute to 20 ⁇ g/ml with coating buffer, add 100 ⁇ l per well to 96-well plate, and let stand overnight at 2 ⁇ 8°C;
- Stop color development 2M H 2 SO 4 is the stop solution, 50 ⁇ l per well to stop color development;
- Reading MD microplate reader reads the absorbance value at 450/655nm respectively, taking the concentration of the sample to be tested as the abscissa and the absorbance value as the ordinate, making a 4-PL curve, and the software automatically gives the EC50 value (see table 7).
- Detection group EC50 value Hib-PLT 0.164nM TGF- ⁇ -R-His 11.60nM Hib-PDV 0.061nM VEGFR-His 2154nM Hib-PDC 24.36nM CD80-His 50.69nM
- the binding capacity of Hib-PLT is compared with TGF- ⁇ receptor monomer: the EC50 value of Hib-PLT is 0.164 nM, the EC50 value of TGF- ⁇ receptor monomer is 11.60 nM, and the binding activity of Hib-PLT is excellent.
- Hib-PDV compared with VEGF receptor monomer The EC50 value of Hib-PDV is 0.061 nM, the EC50 value of VEGF receptor monomer is 2154 nM, and Hib-PDV binding activity It is about 35,311 times better than VEGF receptor monomer;
- Hib-PDC is compared with CD80 monomer: C50 value of Hib-PDC is 24.36 nM, EC50 value of CD80 monomer is 50.69 nM, Hib-PDC binding activity is better than CD80 monomer
- the body is about 2 times. That is, the binding activity of Hib-PLT, Hib-PDV, and Hib-PDC constructed with the bi-antibody model provided by the present invention is much better than the binding activity of their corresponding monomers.
- Example 4 The effect of Hib-PDV on colon cancer MC38 cells transplanted subcutaneously in C57BL/6J-hPD-1 mice
- mice from Shanghai Southern Model Biotechnology Co., Ltd.
- 0.1 mL of colon cancer MC38 cell suspension (1 ⁇ 10 6 cells/mouse) was subcutaneously inoculated into the right abdomen of mice.
- the tumor When the tumor grows to about 100mm 3 , they are randomly grouped according to the size of the tumor and divided into Vehicle (PBS) group, Hib-PDV (1.25mg/kg) group, Hib-PDV (2.5mg/kg) group and Hib-PDV (5mg/kg) group, a total of 4 groups, each group of 8 tumor-bearing mice, intraperitoneal administration, once a week, a total of 3 administrations, during the administration period of 2 times a week to measure the length and shortness of the tumor Diameter and weight.
- the tumor inhibition rate TGI RTV
- Table 8 the tumor inhibition rate
- Table 8 The dosage regimen for the study of Hib-PDV's tumor inhibitory activity on mouse colon cancer
- Dosage (mg/kg) Route of administration Dosing frequency
- Dosing volume Vehicle - i.p. QW ⁇ 3 10mL/kg 2 Hib-PDV 5 i.p. QW ⁇ 3 10mL/kg 3 Hib-PDV 2.5 i.p. QW ⁇ 3 10mL/kg 4 Hib-PDV 1.25 i.p. QW ⁇ 3 10mL/kg
- TGI RTV (%) (1-T RTV /C RTV ) ⁇ 100%
- T RTV represents the RTV of the administration group or the positive control group
- C RTV represents the RTV of the negative control group.
- Hib-PDV's tumor inhibitory effects on mouse colon cancer model are shown in Table 9 and Figure 2.
- Table 9 is Hib-PDV's tumor volume and tumor inhibition rate in mouse colon cancer model
- Figure 2 shows Tumor growth curve after medication.
- Experimental results show that Hib-PDV has a significant inhibitory effect on mouse colon cancer model tumors.
- mice Thirty-two 7-9 weeks old, humanized C57BL/6J humanized PD-1 transgenic female mice (from the southern model) were subcutaneously implanted with 0.1 mL of transgenic hPD-L1MC38 cell suspension ( 1 ⁇ 10 6 cells/piece).
- the tumor When the tumor grows to about 100mm 3 , they are randomly grouped according to the size of the tumor and divided into Vehicle (PBS) group, Hib-PDC (1.25mg/kg) group, Hib-PDC (2.5mg/kg) group, Hib-PDC (5mg/kg)
- PBS Vehicle
- Hib-PDC 1.25mg/kg
- Hib-PDC 2.5mg/kg
- Hib-PDC 5mg/kg
- a total of 4 groups 8 tumor-bearing mice in each group, intraperitoneal administration, once a week, a total of 3 administrations, during the administration period, the tumor’s long diameter, short diameter and body weight were measured twice a week .
- TGI RTV tumor inhibition rate
- Table 10 The dosage regimen for the study of Hib-PDC's tumor inhibitory activity on mouse colon cancer
- Dosage (mg/kg) Mode of administration Dosing volume
- Dosing cycle 1 Vehicle(PBS) - i.p. 10ml/kg QW ⁇ 3 times 2 Hib-PDC 1.25 i.p. 10ml/kg QW ⁇ 3 times 3 Hib-PDC 2.5 i.p. 10ml/kg QW ⁇ 3 times 4 Hib-PDC 5 i.p. 10ml/kg QW ⁇ 3 times
- TGI RTV (%) (1-T RTV /C RTV ) ⁇ 100%
- T RTV represents the RTV of the administration group or the positive control group
- C RTV represents the RTV of the negative control group.
- Table 11 shows the tumor volume and tumor inhibition rate of Hib-PDC on mouse colon cancer models.
- Figure 3 shows the administration After the tumor growth curve.
- the test results show that Hib-PDC has a significant inhibitory effect on subcutaneously transplanted tumors of colorectal cancer in mice.
- Example 6 The effect of Hib-PLT on the secretion of cytokines in the mixed reaction of allogeneic lymphocytes
- ELISA method was used to detect the concentration of cytokine IFN- ⁇ in the cell supernatant to evaluate the effect of Hib-PLT in the activation of CD4 + T cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Abstract
Description
Day0 | 3×10 5/ml,培养体积30ml |
Day4、6、8、10、12 | 900μLCellBoost7A、90uLCellBoost7B |
Day16 | 检测VCD、活率,留样结束 |
检测组 | S01 | S02 | S03 | S04 | S05 | S06 | S07 | S08 | S09 | S10 | S11 |
Hib-PLT | 555.556 | 55.556 | 5.556 | 1.852 | 0.617 | 0.206 | 0.069 | 0.023 | 0.008 | 0.001 | 0.000 |
TGF-β-R-His | 64516.000 | 6451.600 | 645.160 | 215.053 | 71.684 | 23.895 | 7.965 | 2.655 | 0.885 | 0.088 | 0.009 |
检测组 | S01 | S02 | S03 | S04 | S05 | S06 | S07 | S08 | S09 | S10 | S11 |
Hib-PDV | 555.556 | 55.556 | 5.556 | 1.852 | 0.617 | 0.206 | 0.069 | 0.023 | 0.005 | 0.001 | 0.000 |
VEGFR-His | 43478.300 | 4347.830 | 434.783 | 144.928 | 48.309 | 16.103 | 5.368 | 1.789 | 0.358 | 0.036 | 0.004 |
检测组 | S01 | S02 | S03 | S04 | S05 | S06 | S07 | S08 | S09 | S10 | S11 |
Hib-PDC | 1000000 | 100000 | 10000 | 3333.333 | 1111.111 | 370.370 | 123.457 | 41.152 | 13.717 | 1.372 | 0.137 |
CD80-His | 1000000 | 100000 | 10000 | 3333.333 | 1111.111 | 370.370 | 123.457 | 41.152 | 13.717 | 1.372 | 0.137 |
检测组 | EC50值 |
Hib-PLT | 0.164nM |
TGF-β-R-His | 11.60nM |
Hib-PDV | 0.061nM |
VEGFR-His | 2154nM |
Hib-PDC | 24.36nM |
CD80-His | 50.69nM |
组别 | 给药组 | 给药剂量(mg/kg) | 给药途径 | 给药频次 | 给药体积 |
1 | Vehicle | -- | i.p. | QW×3 | 10mL/kg |
2 | Hib-PDV | 5 | i.p. | QW×3 | 10mL/kg |
3 | Hib-PDV | 2.5 | i.p. | QW×3 | 10mL/kg |
4 | Hib-PDV | 1.25 | i.p. | QW×3 | 10mL/kg |
组别 | 给药组 | 给药剂量(mg/kg) | 给药方式 | 给药体积 | 给药周期 |
1 | Vehicle(PBS) | -- | i.p. | 10ml/kg | QW×3次 |
2 | Hib-PDC | 1.25 | i.p. | 10ml/kg | QW×3次 |
3 | Hib-PDC | 2.5 | i.p. | 10ml/kg | QW×3次 |
4 | Hib-PDC | 5 | i.p. | 10ml/kg | QW×3次 |
Claims (45)
- 一种双特异性融合蛋白,所述融合蛋白的结构是在全长的免疫球蛋白G(IgG)的铰链区通过可选的肽接头插入第二结合结构域,所述IgG的Fab区为第一结合结构域;插入第二结合结构域后的所述IgG的重链为所述融合蛋白的重链,所述IgG的轻链为所述融合蛋白的轻链;所述第二结合结构域选自人受体、配体或所述受体、配体的片段和片段组合;其中,所述受体、配体为在天然信号通路中会形成二聚化或多聚化结构以活化或抑制信号通路的受体或配体,且所述第二结合结构域与所述第一结合结构域靶向不同的靶点。
- 根据权利要求1所述的融合蛋白,其特征在于,所述第一结合结构域靶向结合免疫检查点分子或肿瘤抗原。
- 根据权利要求2所述的融合蛋白,其特征在于,所述免疫检查点分子包括PD-1、PD-L1、CTLA-4、LAG-3、FGL1、TIM-3、Galectin-9、TIGIT、CD155、CD47;所述肿瘤抗原包括Claudin 18.2、HER-2、Mesothelin、BCMA、SSTR2、GPRC5D、PSMA、FCRH5、CD33、CD123、CD20、A33、CEA、CD28、DLL3、EGFR、VEGFR、VEGFR2、VEGF-A、Nectin-4、FGFR、C-met、RANKL、PDGF、PDGFR、PDGFRα、DLL4、Ang-1、Ang-2。
- 根据权利要求3所述的融合蛋白,其特征在于,所述第二结合结构域靶向结合人TGF-β、CTLA-4、VEGF、LAG3、CD27、4-1BB、OX40、CD47、FGL1、TLT-2、CD28、HGF、CSF1、CXCL1、CXCL2、CXCL3、CXCL5、CXCL6、CXCL7、CXCL8、CXCL9、CXCL10、CXCL12、GITR、EGF、ICOSL。
- 根据权利要求4所述的融合蛋白,其特征在于,所述受体或配体为人TGF-β受体(TGF-βR)、CD80、CD86、VEGFR、VEGF-trap、FGL1、CD70、4-1BBL、OX40L、SIRPα、B7-H3、C-met、CSF1R、CXCR2、CXCR3、CXCR4、GITRL、EGFR、ICOS。
- 根据权利要求4所述的融合蛋白,其特征在于,所述第一结合结构域和所述第二结合结构域选自以下组合:(1)所述第一结合结构域靶向结合PD-L1,所述第二结合结构域靶向结合人TGF-β、VEGF、FGL1、CD47、CD155、HGF、CSF1、CXCL1、CXCL2、CXCL3、CXCL5、CXCL6、CXCL7、CXCL8、CXCL9、CXCL10、CXCL12、EGF或ICOSL;或(2)所述第一结合结构域靶向结合PD-1,所述第二结合结构域靶向结合人CTLA-4、VEGF、HGF、EGF、CD28、LAG3、CD27、4-1BB或OX40; 或(3)所述第一结合结构域靶向结合CTLA-4,所述第二结合结构域靶向结合人CD28、VEGF、HGF、EGF、LAG3、CD27、4-1BB或OX40;或(4)所述第一结合结构域靶向结合LAG-3,所述第二结合结构域靶向结合人CD28、VEGF、HGF、EGF、CTLA-4、CD27、4-1BB或OX40;或(5)所述第一结合结构域靶向结合FGL1,所述第二结合结构域靶向结合人TGF-β、VEGF、CD47、CD155、HGF、CSF1、CXCL1、CXCL2、CXCL3、CXCL5、CXCL6、CXCL7、CXCL8、CXCL9、CXCL10、CXCL12、EGF或ICOSL;或(6)所述第一结合结构域靶向结合TIM-3,所述第二结合结构域靶向结合人VEGF、HGF、EGF、LAG3、CD27、4-1BB或OX40;或(7)所述第一结合结构域靶向结合Galectin-9,所述第二结合结构域靶向结合人TGF-β、VEGF、CD47、CD155、HGF、CSF1、CXCL1、CXCL2、CXCL3、CXCL5、CXCL6、CXCL7、CXCL8、CXCL9、CXCL10、CXCL12、EGF或ICOSL;或(8)所述第一结合结构域靶向结合TIGIT,所述第二结合结构域靶向结合人TGF-β、HGF、EGF或VEGF;或(9)所述第一结合结构域靶向结合CD155,所述第二结合结构域靶向结合人TGF-β、VEGF、HGF、EGF、CD47或CD155;或(10)所述第一结合结构域靶向结合Claudin 18.2、HER-2、mesothelin、BCMA、SSTR2、GPRC5D、PSMA、FCRH5、CD33、CD123、CD20、A33、CEA、CD28、DLL3、EGFR、VEGFR、VEGFR2、VEGF-A、Nectin-4、FGFR、C-met、RANKL、PDGF、PDGFR、PDGFRα、DLL-4、Ang-1、Ang-2,所述第二结合结构域靶向结合人CTLA-4,TGF-β、VEGF、FGL1、LAG3、4-1BB、OX40、CD27、CD28、CD47、CD155、HGF、CSF1、CXCL1、CXCL2、CXCL3、CXCL5、CXCL6、CXCL7、CXCL8、CXCL9、CXCL10、CXCL12、EGF或ICOSL。
- 根据权利要求6所述的融合蛋白,其特征在于,所述第一结合结构域和所述受体、配体选自以下组合:(1)所述第一结合结构域靶向结合PD-L1,所述受体、配体选自TGF-βRII、VEGFR、LAG-3、SIRPα、TIGIT、C-MET、CSF1R、CXCR2、CXCR3、CXCR4、EGFR或ICOS;或(2)所述第一结合结构域靶向结合PD-1,所述受体、配体选自人CD80、CD86、VEGFR、c-MET、EGFR、FGL1、CD70、4-1BBL或OX40L;或(3)所述第一结合结构域靶向结合CTLA-4,所述受体、配体选自人CD80、CD86、VEGFR、c-MET、EGFR、FGL1、CD70、4-1BBL或OX40L;或(4)所述第一结合结构域靶向结合LAG-3,所述受体、配体选自人VEGFR、c-MET、EGFR、CD80、CD86、CD70、4-1BBL或OX40L;或(5)所述第一结合结构域靶向结合FGL1,所述受体、配体选自人TGF-βRII、VEGFR、SIRPα、TIGIT、c-MET、CSF1R、CXCR2、CXCR3、CXCR4、EGFR或ICOS;或(6)所述第一结合结构域靶向结合TIM-3,所述受体、配体选自人VEGFR、c-MET、EGFR、FGL1、CD70、4-1BBL或OX40L;或(7)所述第一结合结构域靶向结合Galectin-9,所述受体、配体选自人TGF-βRII、VEGFR、SIRPα、TIGIT、c-MET、CSF1R、CXCR2、CXCR3、CXCR4、EGFR或ICOS;或(8)所述第一结合结构域靶向结合TIGIT,所述受体、配体选自人TGF-βRII、c-MET、EGFR或VEGFR;或(9)所述第一结合结构域靶向结合CD155,所述受体、配体选自人TGF-βRII、VEGFR、c-MET、EGFR、SIRPα或TIGIT;或(10)所述第一结合结构域靶向结合Claudin 18.2、HER-2、mesothelin、BCMA、SSTR2、GPRC5D、PSMA、FCRH5、CD33、CD123、CD20、A33、CEA、CD28、DLL3、EGFR、VEGFR、VEGFR2、Nectin-4、FGFR、c-MET、RANKL、PDGF、PDGFR、PDGFRα、DLL4、Ang-1或Ang-2,所述受体、配体选自人CTLA-4,CD80,CD86,TGF-βRII、VEGFR、FGL1、LAG3、4-1BB、OX40、CD27、CD28、CD70、c-MET、SIRPα、TIGIT、CSF1R、CXCR2、CXCR3、CXCR4、EGFR或ICOS。
- 根据权利要求1-7中任一项所述的融合蛋白,其特征在于,所述受体、配体的片段包括受体或配体的胞外区片段、结合结构域片段。
- 根据权利要求7所述的融合蛋白,其特征在于,所述第一结合结构域靶向结合PD-L1;所述第二结合结构域为人TGF-βRII片段;或所述第一结合结构域靶向结合PD-1,所述第二结合结构域选自人CD80 ECD、CD80 IgV区、人CD80IgVIgC、VEGFR1 ECD、VEGFR2 ECD或VEGFR1的第2个细胞外 区域和VEGFR2的第3个细胞外区域组合;或所述第一结合结构域靶向结合Claudin 18.2或HER-2、EGFR,所述第二结合结构域选自人CD80 ECD、CD80 IgV区、人CD80IgVIgC、VEGFR1 ECD、VEGFR2 ECD或VEGFR1的第2个细胞外区域和VEGFR2的第3个细胞外区域组合。
- 根据权利要求9所述的融合蛋白,其特征在于,所述第二结合结构域选自:(1)包含SEQ ID NO:31、131或132所示序列的人TGF-βRII或包含与SEQ ID NO:31、131或132所示序列相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列或与SEQ ID NO:31、131或132所示序列相比具有1个、2个、3个、4个、5个、6个、7个、8个、9个或10个氨基酸替换或缺失后的氨基酸序列;或(2)包含SEQ ID NO:32或133所示序列的CD80 ECD或包含与SEQ ID NO:32或133所示序列相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列或与SEQ ID NO:32或133所示序列相比具有1个、2个、3个、4个、5个、6个、7个、8个、9个或10个氨基酸替换或缺失后的氨基酸序列;或(3)包含SEQ ID NO:33所示序列的VEGFR1的第2个细胞外区域和VEGFR2的第3个细胞外区域片段组合或包含与SEQ ID NO:33所示序列相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列或与SEQ ID NO:33所示序列相比具有1个、2个、3个、4个、5个、6个、7个、8个、9个或10个氨基酸替换或缺失后的氨基酸序列。
- 根据权利要求9或10所述的融合蛋白,其特征在于,所述第一结合结构域靶向结合PD-L1,所述IgG的Fab中重链可变区的CDR和/或所述轻链可变区的CDR与如下序列限定的抗体具有相同的CDR序列或在如下序列限定的抗体的CDR上进行1-2个氨基酸替换,所述序列限定的抗体为:(1)重链可变区氨基酸序列为SEQ ID NO:66所示;和/或(2)轻链可变区氨基酸序列为SEQ ID NO:67所示。
- 根据权利要求11所述的融合蛋白,其特征在于,所述IgG的Fab中重链可变区的CDR和/或所述轻链可变区的CDR如下所示:(1)重链可变区CDR1氨基酸序列选自SEQ ID NO:1-5及对SEQ ID NO:1-5进行1或2个氨基酸替换后的氨基酸序列;CDR2氨基酸序列选自SEQ ID NO:6-10及对SEQ ID NO:6-10进行1或2个氨基酸替换后的氨基酸序列;CDR3氨基酸序列选自SEQ ID NO:11-15及对SEQ ID NO:11-15进行1或2个氨基酸替换后的氨基酸序列;和/或(2)轻链可变区CDR1氨基酸序列选自SEQ ID NO:16-20及对SEQ ID NO:16-20进行1或2个氨基酸替换后的氨基酸序列;CDR2氨基酸序列选自SEQ ID NO:21-25及对SEQ ID NO:21-25进行1或2个氨基酸替换后的氨基酸序列;CDR3氨基酸序列选自SEQ ID NO:26-30及对SEQ ID NO:26-30进行1或2个氨基酸替换后的氨基酸序列。
- 根据权利要求12所述的融合蛋白,其特征在于:(1)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:1,6,11或对SEQ ID NO:1,6,11进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:16,21,26或对SEQ ID NO:16,21,26进行1或2个氨基酸替换后的氨基酸序列;或(2)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:2,7,12或对SEQ ID NO:2,7,12进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:17,22,27或对SEQ ID NO:17,22,27进行1或2个氨基酸替换后的氨基酸序列;或(3)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:3,8,13或对SEQ ID NO:3,8,13进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:18,23,28或对SEQ ID NO:18,23,28进行1或2个氨基酸替换后的氨基酸序列;或(4)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:4,9,14或对SEQ ID NO:4,9,14进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:19,24,29或对SEQ ID NO:19,24,29进行1或2个氨基酸替换后的氨基酸序列;或(5)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:5,10,15或对SEQ ID NO:5,10,15进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:20,25,30或对SEQ ID NO:20,25,30进行1或2个氨基酸替换后的氨基酸序列。
- 根据权利要求13所述的融合蛋白,其特征在于,重链可变区CDR 1-3氨基酸序列为SEQ ID NO:3,8,13;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:18,23,28。
- 根据权利要求14所述的融合蛋白,其特征在于:(1)重链可变区的序列如SEQ ID NO:66所示,或与SEQ ID NO:66具有相同的CDR 1-3且与SEQ ID NO:66相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列;和/或(2)轻链可变区的序列如SEQ ID NO:67所示,或与SEQ ID NO:67具有相同的CDR 1-3且与SEQ ID NO:67相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列。
- 根据权利要求15所述的融合蛋白,其特征在于:(1)所述融合蛋白的重链氨基酸序列如SEQ ID NO:72所示或与SEQ ID NO:72相比同一性大于90%、95%、96%、97%、98%、99%的序列;(2)所述融合蛋白的轻链氨基酸序列分别如SEQ ID NO:73所示或与SEQ ID NO:73相比同一性大于90%、95%、96%、97%、98%、99%的序列。
- 根据权利要求16所述的融合蛋白,其特征在于:(1)所述融合蛋白的重链氨基酸序列与SEQ ID NO:72相比具有1-15个氨基酸位点突变或具有替换的肽接头;(2)所述融合蛋白的轻链氨基酸序列与SEQ ID NO:73相比具有1-10个氨基酸位点突变。
- 根据权利要求9所述的融合蛋白,其特征在于,所述第一结合结构域靶向结合PD-1,所述IgG的Fab中重链可变区的CDR和/或所述轻链可变区的CDR与如下序列限定的抗体具有相同的CDR序列或在如下序列限定的抗体的CDR上进行1-2个氨基酸替换,所述序列限定的抗体为:(1)重链可变区氨基酸序列为SEQ ID NO:64所示;和/或(2)轻链可变区氨基酸序列为SEQ ID NO:65所示。
- 根据权利要求18所述的融合蛋白,其特征在于,所述IgG的Fab中重链可变区的CDR和/或所述轻链可变区的CDR如下所示:(1)重链可变区CDR1氨基酸序列选自SEQ ID NO:34-38及对SEQ ID NO:34-38进行1或2个氨基酸替换后的氨基酸序列;CDR2氨基酸序列选自SEQ ID NO:39-43及对SEQ ID NO:39-43进行1或2个氨基酸替换后的氨基酸序列;CDR3氨基酸序列选自SEQ ID NO:44-48及对SEQ ID NO:44-48进行1或2个氨基酸替换后的氨基酸序列;和/或(2)轻链可变区CDR1氨基酸序列选自SEQ ID NO:49-53及对SEQ ID NO:49-53进行1或2个氨基酸替换后的氨基酸序列;CDR2氨基酸序列选自SEQ ID NO:54-58及对SEQ ID NO:54-58进行1或2个氨基酸替换后的氨基酸序列;CDR3氨基酸序列选自SEQ ID NO:59-63及对SEQ ID NO:59-63进行1或2个氨基酸替换后的氨基酸序列。
- 根据权利要求19所述的融合蛋白,其特征在于:(1)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:34,39,44或对SEQ ID NO:34,39,44进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:49,54,59或对SEQ ID NO:49,54,59进行1或2个氨基酸替换后的氨基酸序列;或(2)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:35,40,45或对SEQ ID NO:35,40,45进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:50,55,60或对SEQ ID NO:50,55,60进行1或2个氨基酸替换后的氨基酸序列;或(3)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:36,41,46或对SEQ ID NO:36,41,46进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:51,56,61或对SEQ ID NO:51,56,61进行1或2个氨基酸替换后的氨基酸序列;或(4)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:37,42,47或对SEQ ID NO:37,42,47进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:52,57,62或对SEQ ID NO:52,57,62进行1或2个氨基酸替换后的氨基酸序列;或(5)重链可变区CDR 1-3氨基酸序列为SEQ ID NO:38,43,48或对SEQ ID NO:38,43,48进行1或2个氨基酸替换后的氨基酸序列;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:53,58,63或对SEQ ID NO:53,58,63进行1或2个氨基酸替换后的氨基酸序列。
- 根据权利要求20所述的融合蛋白,其特征在于,重链可变区CDR 1-3氨基酸序列为SEQ ID NO:36,41,46;和/或轻链可变区CDR 1-3氨基酸序列为SEQ ID NO:51,56,61。
- 根据权利要求21所述的融合蛋白,其特征在于:(1)重链可变区的序列如SEQ ID NO:64所示,或与SEQ ID NO:64具有 相同的CDR 1-3且与SEQ ID NO:64相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列;和/或(2)轻链可变区的序列如SEQ ID NO:65所示,或与SEQ ID NO:65具有相同的CDR 1-3且与SEQ ID NO:65相比同一性大于80%、85%、90%、95%、96%、97%、98%、99%的序列。
- 根据权利要求22所述的融合蛋白,其特征在于:(1)所述融合蛋白的重链氨基酸序列如SEQ ID NO:68所示或与SEQ ID NO:68相比同一性大于90%、95%、96%、97%、98%、99%的序列;(2)所述融合蛋白的轻链氨基酸序列分别如SEQ ID NO:69所示或与SEQ ID NO:69相比同一性大于90%、95%、96%、97%、98%、99%的序列。
- 根据权利要求23所述的融合蛋白,其特征在于:(1)所述融合蛋白的重链氨基酸序列与SEQ ID NO:68相比具有1-15个氨基酸位点突变或具有替换的肽接头;(2)所述融合蛋白的轻链氨基酸序列与SEQ ID NO:69相比具有1-10个氨基酸位点突变。
- 根据权利要求22所述的融合蛋白,其特征在于:(1)所述融合蛋白的重链氨基酸序列如SEQ ID NO:70所示或与SEQ ID NO:70相比同一性大于90%、95%、96%、97%、98%、99%的序列;(2)所述融合蛋白的轻链氨基酸序列分别如SEQ ID NO:71所示或与SEQ ID NO:71相比同一性大于90%、95%、96%、97%、98%、99%的序列。
- 根据权利要求25所述的融合蛋白,其特征在于:(1)所述融合蛋白的重链氨基酸序列与SEQ ID NO:70相比具有1-15个氨基酸位点突变或具有替换的肽接头;(2)所述融合蛋白的轻链氨基酸序列与SEQ ID NO:71相比具有1-10个氨基酸位点突变。
- 根据权利要求1-10中任一项所述的融合蛋白,其特征在于:所述IgG为Atezolizumab、Avelumab、Durvalumab、Nivolumab、Pembrolizumab、Cemiplimab、Ipilimumab。
- 根据权利要求1-27中任一项所述的融合蛋白,其特征在于,所述第二结合结构域的C端或/和N端带有肽接头,所述肽接头由2-30个氨基酸组 成。
- 根据权利要求28所述的融合蛋白,其特征在于,所述肽接头为:(1)(GGGGS)n;或(2)AKTTPKLEEGEFSEAR(SEQ ID NO:80);或(3)AKTTPKLEEGEFSEARV(SEQ ID NO:81);或(4)AKTTPKLGG(SEQ ID NO:82);或(5)SAKTTPKLGG(SEQ ID NO:83);或(6)SAKTTP(SEQ ID NO:84);或(7)RADAAP(SEQ ID NO:85);或(8)RADAAPTVS(SEQ ID NO:86);或(9)RADAAAAGGPGS(SEQ ID NO:87);或(10)RADAAAA(SEQ ID NO:88);或(11)SAKTTPKLEEGEFSEARV(SEQ ID NO:89);或(12)ADAAP(SEQ ID NO:90);或(13)DAAPTVSIFPP(SEQ ID NO:91);或(14)TVAAP(SEQ ID NO:92);或(15)TVAAPSVFIFPP(SEQ ID NO:93);或(16)QPKAAP(SEQ ID NO:94);或(17)QPKAAPSVTLFPP(SEQ ID NO:95);或(18)AKTTPP(SEQ ID NO:96);或(19)AKTTPPSVTPLAP(SEQ ID NO:97);或(20)AKTTAP(SEQ ID NO:98);或(21)AKTTAPSVYPLAP(SEQ ID NO:99);或(22)ASTKGP(SEQ ID NO:100);或(23)ASTKGPSVFPLAP(SEQ ID NO:101);或(24)GENKVEYAPALMALS(SEQ ID NO:102);或(25)GPAKELTPLKEAKVS(SEQ ID NO:103);或(26)GHEAAAVMQVQYPAS(SEQ ID NO:104);或(27)GGGGSGGGGSGGGGSA(SEQ ID NO:105),其中所述n等于1、2、3或4。
- 根据权利要求1-29中任一项所述的融合蛋白,其特征在于,插入的所述第二结合结构域的大小不超过300个氨基酸。
- 根据权利要求1-30中任一项所述的融合蛋白,其特征在于,所述第二结合结构域的插入位点位于铰链区的中前部,插入位点不影响免疫球蛋白的二硫键的形成。
- 根据权利要求31所述的融合蛋白,其特征在于,所述铰链区的中前部是指231A之前的部分。
- 根据权利要求1-32中任一项所述的融合蛋白,其特征在于,所述插入位点前后铰链区的部分氨基酸被替换或缺失。
- 根据权利要求33所述的融合蛋白,其特征在于,所述铰链区含有D221G和/或C220V突变。
- 根据权利要求1-34中任一项所述的融合蛋白,其特征在于,所述IgG选自哺乳动物IgG、人源化IgG和人IgG,所述哺乳动物包括小鼠、大鼠、兔;优选的,所述IgG为IgG1、IgG2、IgG3、IgG4。
- 根据权利要求1-35中任一项所述的融合蛋白,其特征在于,该融合蛋白的Fc区是无糖基化的或脱糖基化的或具有降低的岩藻糖基化或是无岩藻糖基化的。
- 分离的多核苷酸,其编码权利要求1-36中任一项所述的融合蛋白。
- 一种核酸构建体,其包含权利要求37所述的多核苷酸,优选所述核酸构建体为载体。
- 一种宿主细胞,其包含权利要求37所述的多核苷酸或者权利要求38所述的核酸构建体或所述载体,优选的所述细胞是原核细胞、真核细胞、酵母细胞、哺乳动物细胞、大肠杆菌细胞或CHO细胞、NS0细胞、Sp2/0细胞、BHK细胞。
- 药物组合物,包含权利要求1-36中任一项所述的融合蛋白以及药学上可接受的载体。
- 用于治疗肿瘤或癌症的方法,其包括对需要治疗或减轻的受试者施用 权利要求1-36中任一项的融合蛋白或权利要求40的药物组合物的步骤。
- 权利要求1-36中任一项所述的融合蛋白、权利要求37所述的多核苷酸、权利要求38所述的核酸构建体或者所述载体、或权利要求40所述的药物组合物在制备用于治疗或预防肿瘤或癌症的药物中的用途。
- 根据权利要求42所述的用途,其特征在于,所述的肿瘤或癌症包括实体瘤或非实体瘤。
- 诊断试剂盒,其包含权利要求1-36中任一项所述的融合蛋白。
- 权利要求1至36中任一项的融合蛋白的生产方法,该方法包括:在允许权利要求38所述的核酸构建体表达的条件下培养权利要求39所述的宿主细胞,并从培养物中回收产生的融合蛋白。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021237513A AU2021237513A1 (en) | 2020-03-20 | 2021-03-19 | Bispecific fusion protein and application thereof |
CA3137211A CA3137211A1 (en) | 2020-03-20 | 2021-03-19 | Bispecific fusion protein and application thereof |
KR1020227022059A KR20220107257A (ko) | 2020-03-20 | 2021-03-19 | 이중특이성 융합 단백질 및 그의 응용 |
CN202180005265.9A CN114466868A (zh) | 2020-03-20 | 2021-03-19 | 一种双特异性融合蛋白及其应用 |
US17/594,768 US20220204626A1 (en) | 2020-03-20 | 2021-03-19 | Bispecific fusion protein and application thereof |
JP2022539415A JP7489468B2 (ja) | 2020-03-20 | 2021-03-19 | 二重特異性融合タンパク質及びその応用 |
EP21770764.5A EP4056596A4 (en) | 2020-03-20 | 2021-03-19 | BISPECIFIC FUSION PROTEIN AND USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010199036 | 2020-03-20 | ||
CN202010199036.2 | 2020-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021185337A1 true WO2021185337A1 (zh) | 2021-09-23 |
Family
ID=77769172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/081659 WO2021185337A1 (zh) | 2020-03-20 | 2021-03-19 | 一种双特异性融合蛋白及其应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220204626A1 (zh) |
EP (1) | EP4056596A4 (zh) |
JP (1) | JP7489468B2 (zh) |
KR (1) | KR20220107257A (zh) |
CN (1) | CN114466868A (zh) |
AU (1) | AU2021237513A1 (zh) |
CA (1) | CA3137211A1 (zh) |
TW (1) | TW202136315A (zh) |
WO (1) | WO2021185337A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023066322A1 (zh) * | 2021-10-21 | 2023-04-27 | 杭州阿诺生物医药科技有限公司 | 一种融合多肽及其用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022521958A (ja) * | 2019-08-29 | 2022-04-13 | 榮昌生物制薬(烟台)股▲フン▼有限公司 | 抗pd-l1抗体及びその応用 |
WO2024028386A1 (en) * | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024114605A1 (zh) * | 2022-11-29 | 2024-06-06 | 杭州阿诺生物医药科技有限公司 | 一种融合多肽及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015118175A2 (en) | 2014-02-10 | 2015-08-13 | Merck Patent Gmbh | TARGETED TGFβ INHIBITION |
CN109721657A (zh) * | 2017-10-27 | 2019-05-07 | 北京比洋生物技术有限公司 | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 |
US20200002439A1 (en) * | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Trispecific antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018013677A2 (pt) * | 2016-01-11 | 2019-01-22 | Inhibrx Inc | proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas |
AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
EP3694890A4 (en) * | 2017-10-12 | 2021-11-03 | Immunowake Inc. | LIGHT CHAIN ANTIBODY FUSION PROTEIN WITH VEGFR |
SG11202100208VA (en) * | 2018-07-09 | 2021-02-25 | Precigen Inc | Fusion constructs and methods of using thereof |
-
2021
- 2021-03-19 AU AU2021237513A patent/AU2021237513A1/en active Pending
- 2021-03-19 EP EP21770764.5A patent/EP4056596A4/en active Pending
- 2021-03-19 CA CA3137211A patent/CA3137211A1/en active Pending
- 2021-03-19 US US17/594,768 patent/US20220204626A1/en active Pending
- 2021-03-19 TW TW110110024A patent/TW202136315A/zh unknown
- 2021-03-19 CN CN202180005265.9A patent/CN114466868A/zh active Pending
- 2021-03-19 WO PCT/CN2021/081659 patent/WO2021185337A1/zh unknown
- 2021-03-19 KR KR1020227022059A patent/KR20220107257A/ko unknown
- 2021-03-19 JP JP2022539415A patent/JP7489468B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015118175A2 (en) | 2014-02-10 | 2015-08-13 | Merck Patent Gmbh | TARGETED TGFβ INHIBITION |
CN106103488A (zh) * | 2014-02-10 | 2016-11-09 | 默克专利有限公司 | 靶向TGFβ抑制 |
CN109721657A (zh) * | 2017-10-27 | 2019-05-07 | 北京比洋生物技术有限公司 | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 |
US20200002439A1 (en) * | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Trispecific antagonists |
Non-Patent Citations (7)
Title |
---|
ARAN F. LABRIJN ET AL.: "Bispecific antibodies: a mechanistic review of the pipeline", NATURE REVIEWS DRUG DISCOVERY, vol. 18, 2019, pages 585 - 608 |
BINYAM BEZABEH ET AL.: "Insertion of scFv into the Hinge Domain of Fulllength IgGl Monoclonal Antibody Results in Tetravalent Bispecific Molecule with Robust Properties", MABS, vol. 9, no. 2, 16 December 2016 (2016-12-16), pages 240 - 256, XP055465779, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1270492 * |
DOVEDI, S. ET AL.: "MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells", CANCER RES., vol. 78, no. 13, 2018, XP055696822, DOI: 10.1158/1538-7445.AM2018-2776 |
HEDVAT, M. ET AL.: "Simultaneous checkpoint —checkpoint or checkpoint — costimulatory receptortargeting with bispecific antibodies promotes enhanced human T cell activation [abstract P664", PRESENTED AT THE 2018 SOCIETY FOR IMMUNOTHERAPYOF CANCER (SITC, 2018 |
See also references of EP4056596A4 |
SPIESS CZHAI QCARTER P J: "Alternative molecular formats and therapeutic applications for bispecific antibodies [J", MOLECULAR IMMUNOLOGY, vol. 67, no. 2, 2015, pages 95 - 106, XP029246892, DOI: 10.1016/j.molimm.2015.01.003 |
WOLCHOK, J. D. ET AL.: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma", N.ENGL. J. MED., vol. 377, no. 14, 2017, pages 1345 - 1356 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023066322A1 (zh) * | 2021-10-21 | 2023-04-27 | 杭州阿诺生物医药科技有限公司 | 一种融合多肽及其用途 |
Also Published As
Publication number | Publication date |
---|---|
EP4056596A1 (en) | 2022-09-14 |
AU2021237513A1 (en) | 2021-11-11 |
TW202136315A (zh) | 2021-10-01 |
JP2023509005A (ja) | 2023-03-06 |
KR20220107257A (ko) | 2022-08-02 |
CA3137211A1 (en) | 2021-09-23 |
JP7489468B2 (ja) | 2024-05-23 |
CN114466868A (zh) | 2022-05-10 |
EP4056596A4 (en) | 2023-01-25 |
US20220204626A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021185337A1 (zh) | 一种双特异性融合蛋白及其应用 | |
TWI788286B (zh) | 三特異性和/或三價結合蛋白 | |
JP2020536543A5 (zh) | ||
US20200024358A1 (en) | Trispecific antigen binding proteins | |
JP2022552183A (ja) | 特性が改善されたpd-1標的化il-15/il-15rαfc融合タンパク質 | |
JP2022521937A (ja) | NKp30に結合する抗体分子およびその使用 | |
CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
JP2020510659A (ja) | Cd16a指向性nk細胞エンゲージメント用タンデムダイアボディ | |
WO2021218684A1 (zh) | 四价双特异性抗体、其制备方法和用途 | |
US20230183342A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
TWI806087B (zh) | 免疫細胞銜接多特異性結合蛋白及其製備和應用 | |
US20210380691A1 (en) | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders | |
CN111971090A (zh) | 双特异性egfr/cd16抗原结合蛋白 | |
WO2020135804A1 (zh) | 异源二聚体融合蛋白 | |
CN110872356B (zh) | 双特异性抗体及其使用方法 | |
JP2023518686A (ja) | Bcmaに特異的な抗体およびキメラ抗原受容体 | |
Baeuerle | Development of T‐Cell‐Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B‐Cell Malignancies | |
WO2023011650A1 (zh) | 一种多特异性抗体及其用途 | |
WO2023045977A1 (zh) | 白介素2突变体以及其融合蛋白 | |
WO2023199927A1 (ja) | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用 | |
CN114773485B (zh) | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 | |
WO2022063314A1 (zh) | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 | |
WO2022037582A1 (zh) | 抗cd3和抗cldn-18.2双特异性抗体及其用途 | |
WO2024121414A1 (en) | Chimeric antigen receptor | |
RU2021131461A (ru) | Биспецифичный слитый белок и его применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3137211 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21770764 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021237513 Country of ref document: AU Date of ref document: 20210319 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021770764 Country of ref document: EP Effective date: 20220610 |
|
ENP | Entry into the national phase |
Ref document number: 2022539415 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227022059 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |